Reches, A., Ophir, Y., Stein, N., Kol, I., Isaacson, B., Charpak Amikam, Y. ... Mandelboim, O. (2020). Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer, 8. (1). doi: 10.1136/jitc-2019-000266
Reches, Adi, et al. "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity." Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, 2020. https://doi.org/10.1136/jitc-2019-000266
Reches, Adi, Yael Ophir, Natan Stein, Inbal Kol, Batya Isaacson, Yoav Charpak Amikam, Afek Elnekave, et al. "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity." Journal for ImmunoTherapy of Cancer 8, no. 1 (2020). https://doi.org/10.1136/jitc-2019-000266
Reches, A., et al. (2020) 'Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity', Journal for ImmunoTherapy of Cancer, 8(1). doi: 10.1136/jitc-2019-000266
Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, and sur.. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer [Internet]. 2020 June [cited 2024 August 20];8(1). doi: 10.1136/jitc-2019-000266
A. Reches, et al., "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity", Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, June 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:706583. [Accessed: 20 August 2024]